We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $3.85B
1-Year Est. Return 32.11%
This Fund
S&P 500
This Quarter Est. Return
+9.18%
1 Year Est. Return
+32.11%
3 Year Est. Return
+93.86%
5 Year Est. Return
+112.79%
10 Year Est. Return
+380.9%
AUM
$1.2B
AUM Growth
-$255M
Cap. Flow
-$342M
Cap. Flow %
-28.37%
Top 10 Hldgs %
51.29%
Holding
4,943
New
709
Increased
1,153
Reduced
1,646
Closed
1,310

Sector Composition

Rank Sector Weight
1 Technology 2.73%
2 Financials 2.53%
3 Healthcare 2.3%
4 Consumer Discretionary 2.11%
5 Industrials 1.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NVT icon
576
nVent Electric
NVT
$26.4B
$202K 0.02%
7,899
+3,768
+91% +$87.6K
GAP
577
The Gap Inc
GAP
$7.39B
$201K 0.02%
11,359
-3,066
-21% -$52.2K
PRNB
578
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$201K 0.02%
3,674
+2,930
+394% +$109K
CADE
579
DELISTED
Cadence Bancorporation
CADE
$201K 0.02%
+11,076
New +$185K
CPRT icon
580
Copart
CPRT
$26.9B
$200K 0.02%
8,788
-3,604
-29% -$76.9K
LLY icon
581
Eli Lilly
LLY
$1.06T
$200K 0.02%
1,519
-11,276
-88% -$1.31M
AGIO icon
582
Agios Pharmaceuticals
AGIO
$1.91B
$199K 0.02%
4,171
+3,507
+528% +$133K
CRL icon
583
Charles River Laboratories
CRL
$12.8B
$199K 0.02%
1,304
+707
+118% +$97.9K
KRE icon
584
State Street SPDR S&P Regional Banking ETF
KRE
$4.65B
$199K 0.02%
3,413
-42,653
-93% -$2.36M
NKTR icon
585
Nektar Therapeutics
NKTR
$2.48B
$199K 0.02%
614
+36
+6% +$10.4K
QGEN icon
586
Qiagen
QGEN
$8.61B
$199K 0.02%
5,556
+3,913
+238% +$145K
RAMP icon
587
LiveRamp
RAMP
$2.3B
$199K 0.02%
4,136
+153
+4% +$6.88K
SON icon
588
Sonoco
SON
$5.64B
$199K 0.02%
3,232
+1,656
+105% +$98K
WRI
589
DELISTED
Weingarten Realty Investors
WRI
$199K 0.02%
6,376
+2,668
+72% +$81.6K
AMGN icon
590
Amgen
AMGN
$219B
$198K 0.02%
823
-6,956
-89% -$1.53M
ICUI icon
591
ICU Medical
ICUI
$4.16B
$198K 0.02%
1,057
+971
+1,129% +$167K
ONB icon
592
Old National Bancorp
ONB
$10.2B
$198K 0.02%
10,843
+6,591
+155% +$118K
CLB icon
593
Core Laboratories
CLB
$513M
$197K 0.02%
5,220
+4,897
+1,516% +$220K
UBSI icon
594
United Bankshares
UBSI
$6.65B
$197K 0.02%
5,087
+1,801
+55% +$69.5K
UL icon
595
Unilever
UL
$137B
$197K 0.02%
3,069
+949
+45% +$63K
CCXI
596
DELISTED
ChemoCentryx, Inc.
CCXI
$197K 0.02%
4,993
+3,548
+246% +$62.3K
FNDX icon
597
Schwab Fundamental US Large Company Index ETF
FNDX
$27.2B
$196K 0.02%
13,830
-20,646
-60% -$282K
MRNA icon
598
Moderna
MRNA
$21.5B
$196K 0.02%
10,017
+5,491
+121% +$97.4K
VRTX icon
599
Vertex Pharmaceuticals
VRTX
$123B
$196K 0.02%
897
-4,736
-84% -$958K
LZB icon
600
La-Z-Boy
LZB
$1.63B
$195K 0.02%
+6,182
New +$207K

Similar funds

Tower Research Capital (TRC)'s Q4 2019 Portfolio in Review

As of Q4 2019, Tower Research Capital (TRC) held 4,943 positions worth $1.2B, down 17% from $1.46B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Tower Research Capital (TRC) withdrew a net $342M in Q4 2019, closing 1,310 positions and reducing 1,646 holdings. Its most notable exit was Wells Fargo, an estimated $7.5M position sold in full.

By sector, the portfolio is most concentrated in Technology at 2.7% of assets, down from 9.1% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Tower Research Capital (TRC) opened a new position in iShares Core S&P 500 ETF worth $24.4M.

  • Tower Research Capital (TRC)'s largest Q4 2019 buy was iShares Core S&P 500 ETF: 75,634 shares worth $24.4M.
  • Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q4 2019, an estimated $168M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2019 reduction was State Street Consumer Staples Select Sector SPDR ETF, cutting an estimated $52.3M.
  • Tower Research Capital (TRC) fully exited Wells Fargo in Q4 2019, selling an estimated $7.5M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 51% of its $1.2B portfolio in Q4 2019.
  • Tower Research Capital (TRC) opened 709 new positions and closed 1,310 in Q4 2019.
  • Tower Research Capital (TRC)'s portfolio value fell 17% quarter-over-quarter to $1.2B.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.